Galmed Pharmaceuticals (NASDAQ:GLMD) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report issued on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Stock Up 2.5 % Shares of GLMD opened at $0.28 on Thursday. Galmed Pharmaceuticals has a 52-week low of $0.26 and a 52-week high […]
30 Jun 04:48 · The Cerbat Gem